Effects of succinylcholine at the masseter and adductor pollicis muscles in adults.

The effect of succinylcholine on baseline tension and evoked twitch height was measured at the masseter and the adductor pollicis muscles in ten adults undergoing elective surgery. During thiopental-nitrous oxide-enflurane (end-tidal concentration less than 0.25%) anesthesia, supramaximal stimulation was applied to both the ulnar nerve and the nerve to the masseter. Baseline tension and the isometric force of contraction were measured at the jaw and the thumb. Cumulative dose-response relationships were obtained by giving succinylcholine in incremental doses (initial dose, 0.10 mg/kg, followed by 0.05- or 0.1-mg/kg increments, depending on response). An infusion was started after the maximum effect of the first dose, at a rate adjusted to compensate for the rapid metabolism of the drug. There was no difference between the sensitivity of the masseter and the adductor pollicis. The ED50 values were (mean +/- SEM) 0.11 +/- 0.01 mg/kg at both muscles. The ED90 values were 0.17 +/- 0.02 mg/kg at the masseter and 0.16 +/- 0.01 mg/kg at the adductor pollicis. Onset of action was more rapid at the masseter. In six of the ten patients, baseline tension at the jaw was found to increase by a mean of 80 +/- 24 g (range 25-188 g). It is concluded that in adults, masseter neuromuscular blockade can be achieved with succinylcholine doses approximately equal to those required to block the adductor pollicis. In addition, the drug may cause increased tension in the muscles of the jaw.

Differential effects of pancuronium on masseter and adductor pollicis muscles in humans.

The sensitivity of the masseter, one of the muscles of the upper airway, to pancuronium was measured in ten adults undergoing elective surgery and compared with that of the adductor pollicis. During thiopental-nitrous oxide-enflurane (end-tidal concentration less than 0.25%) anesthesia, supramaximal nerve stimulation was applied to the ulnar nerve at the elbow and to the nerve to the masseter, at a point inferior to the zygomatic arch, anterior to the mandibular condyle. Jaw closure was measured by a force transducer system attached to both an oral airway and a metal frame fixed to the operating table 10 cm caudad to the chin. Cumulative dose-response curves for pancuronium (initial dose = 0.02 mg/kg, incremental doses = 0.01 mg/kg) were determined. Control twitch tensions were (mean +/- SEM) 473 +/- 75 g at the masseter and 660 +/- 118 g at the adductor pollicis. The masseter was slightly more sensitive to pancuronium, the ED50 being 0.024 +/- 0.001 mg/kg compared with 0.028 +/- 0.001 mg/kg for the adductor pollicis (P less than 0.05). Corresponding values for the ED90 were 0.038 +/- 0.004 and 0.043 +/- 0.002 mg/kg, respectively (P less than 0.05). The time from injection of the first dose of pancuronium to maximum blockade was 3.2 +/- 0.2 min at the masseter and 3.8 +/- 0.2 min at the adductor pollicis (P less than 0.01). Following incremental doses, this time was 1.8 +/- 0.1 and 2.6 +/- 0.1 min, respectively (P less than 0.01). It is concluded that after injection of pancuronium, neuromuscular blockade is greater at the masseter and occurs sooner than at the adductor pollicis. Jaw relaxation can be achieved with relatively small doses of pancuronium. This suggests that return of adductor pollicis function may not imply complete masseter muscle recovery.